Why 660nm and 850nm outperform every other light therapy wavelength.

Not all red light is created equal. Walk through any wellness aisle and you'll see dozens of devices branded as "red light therapy" — most selling for £30 to £80, most backed by nothing more than a glossy marketing page. The problem isn't the idea. The problem is the wavelength. Cheap LEDs emit mixed frequencies that look impressively red to the human eye but penetrate skin poorly, scatter across the wrong depths, and trigger almost no meaningful cellular response. Two specific wavelengths — 660nm and 850nm — are the only ones that carry real, reproducible clinical evidence. Everything else is a light bulb with good branding.

660nm (visible red) penetrates roughly 2mm into the skin — precisely the depth at which fibroblasts produce collagen, hair follicles anchor into the dermis, and surface-level cells repair damage. This is the wavelength with the strongest human-trial evidence for visible skin and scalp outcomes, and it's the reason dermatology clinics calibrate their LED panels to this specific frequency.

850nm (near-infrared) is invisible to the human eye but penetrates roughly 5mm — reaching muscle, connective tissue, joints, and the deeper vascular beds that feed hair follicles from below. 850nm is where the mitochondrial ATP-production effect peaks, which is why near-infrared wavelengths dominate the photobiomodulation literature for recovery, inflammation, and deep-tissue repair.

The cheap LEDs that dominate the consumer market claim "red light therapy" while emitting across a noisy 620–680nm band with wide variance. Even when a device technically hits the right centre wavelength, power output (irradiance) is rarely measured or disclosed — which means a 10-minute session might deliver a therapeutic dose or a fraction of one, with no way to tell. Lumisca devices are calibrated against medical-grade tolerances: dual 660nm + 850nm emitters, irradiance tested to within ±5% of target, and session length engineered for a measured dose, not a guess.

A 2014 controlled trial out of Mexico, published in Lasers in Surgery and Medicine, compared single-wavelength red light therapy against combined 660nm + 850nm therapy in participants with androgenetic alopecia. After 16 weeks the combination arm showed a 35% greater increase in hair density than the single-wavelength arm. The finding has been replicated across subsequent trials, and is the reason every serious LLLT device now ships with both wavelengths rather than one.